PathoGenetix
	Developer of an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning (GSS) technology. The companyâ€™s technology analyzes an enriched biological sample without the need for a cultured isolate and also provides results in five hours.
	['', 'automated system', ' ', 'rapid identification', ' ', 'bacterial strain', ' ', 'genome sequence', ' ', 'scanning technology', ' ', 'pathogen detection', ' ', 'bacterial strain', ' pathogen']
Thallion Pharmaceuticals
	Developer of pharmaceutical products in the areas of infectious disease and oncology. The company\'s clinical program Shigamabs is a dual antibody product for the treatment of Shiga toxin-producing E. coli ("STEC") bacterial infections.
	['', 'infectious disease', ' ', 'antibody product', ' ', 'bacterial infection', ' oncology']
Inimex Pharmaceuticals
	Developer of innate defense regulators (IDRs) that trigger the body\'s innate defenses without causing inflammation. The company provides product which is active against normal and drug resistant bacteria and used to stimulate host innate immune defenses. Its products are used to treat infections in immune suppressed patients, antibiotic resistant hospital infections, and the management of inflammatory and cancer disease.
	['', 'developer of drung', '  ', 'innate immune defense', ' ', 'drug resistant bacteria', '']
NanoAntibiotics
	Developer of antibiotics to treat multi drug resistant bacterias. The company engages in the discovery, development and commercialization of antibiotics.
	['', 'antibiotic treatment', ' ', 'drug resistant bacteria', ' ', 'nano technology', '']
RQx Pharmaceuticals
	Developer of broad spectrum small molecule antibiotics. The company\'s antibiotics are developed for life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria.
	['', 'antibiotic developer', ' ', 'drug resistant infection', ' ', 'broad spectrum antibiotic', ' ', 'molecule antibiotics', ' ', 'life threatening infections', ' ', 'healthcare industry', '']
Mpex Pharmaceuticals
	Developer of therapies for antibiotic resistance. The company offers MP-376, a proprietary formula of levofloxacin that is developed clinically as a maintenance therapy for the prevention of bacterial exacerbations in patients with cystic fibrosis and chronic obstructive pulmonary diseases. It also provides inhibitors of bacterial multi-drug resistant efflux pumps, which are source of drug resistance in gram-negative pathogens, such as Pseudomonas aeruginosa and gram-positive pathogens, such as methicillin-resistant staphylococcus aureus. It has a strategic alliance with GlaxoSmithKline.
	['', 'antibiotic resistance therapy', ' ', 'gram-negative organism', ' antibiotic ', 'aerosol formulation', ' ', 'bacterial exacerbation', '']
Cempra Pharmaceuticals
	Developer of medicines for curing bacterial infections. The company discovers and develops differentiated medicines that cure bacterial infections. It develops antibiotics to treat multi-drug resistant bacterial infections.
	['', 'bacterial infection', ' ', 'infection treatment', ' ', 'infection medicine', ' ', 'drug resistant bacteria', ' ', 'bacterial antibiotics', '']
Creatogen
	Developer of technology for genome wide functional genomics. The company develops bacterial carriers for oral delivery to treat and to prevent acute and chronic diseases caused by an imbalance of the immune system. The company also develops a bird flu vaccine for poultry.
	['genomics ', 'bacterial carriers', ' ', 'oral delivery', ' ', 'chronic diseases', ' ', 'immune system', ' ', 'bird flu vaccine', '']
GlycoVaxyn
	Developer of a portfolio of bioconjugate vaccines to prevent and treat bacterial infections. The company\'s technology enables the development and production of immunogenic glycoproteins (polysaccharide and protein complexes) for use as conjugated vaccines. It has the ability to conjugate any carbohydrate to almost any protein resulting in a well-characterized molecule with high consistency and batch-to-batch reproducibility enabling the targeting of bacterial diseases.
	['', 'immunogenic glycoprotein', ' ', 'bioconjugate vaccine', ' ', 'bacterial disease', '']
Achaogen
	Developer of antibacterial therapies for treating multi-drug resistant (MDR) infections. The company is focused on the discovery, development and commercialization of antibacterials to treat MDR gram-negative infections. Its lead product candidate is plazomcin, designed to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, or CRE.
	['', 'bacterial infection', ' ', 'antibiotic resistant', ' ', 'antibacterial compound', ' ', 'drug-resistant', '']
Sequoia Pharmaceuticals
	Developer of drugs to combat drug-resistant viral infections.
	['', 'drug resistant infection', ' ', 'viral infection', '']
